 |
|
|
| |
A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1-6 HCV Infection:
The POLARIS-4 Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Stefan Zeuzem1, Steven L. Flamm2, Myron Tong3, John M. Vierling4, Stephen Pianko5, Peter Buggisch6, Victor de Lédinghen7, Robert H. Hyland8, Xiaoru Wu8, KC Huang8, Evguenia S. Svarovskaia8, Luisa M. Stamm8, Diana M. Brainard8, G. Mani Subramanian8, John G. McHutchison8, Elizabeth C. Verna9, Meena B. Bansal10, Charles S. Landis11, Simone I. Strasser12, Curtis L. Cooper13, Kris Kowdley14
1 Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany; 2 Northwestern University, Chicago, IL; 3 Huntington Medical Research Institutes, Pasadena, CA; 4 Baylor College of Medicine, Houston, TX; 5 Monash University, Clayton, Victoria, Australia; 6 ifi -Institute for Interdisciplinary Medicine, Hamburg, Germany; 7 University Hospital of Bordeaux, Pessac, France; 8 Gilead Sciences, Inc., Foster City, CA; 9 Columbia University Medical Center, New York, NY; 10 Ichan School of Medicine at Mount Sinai, New York, NY; 11 University of Washington, Seattle, WA; 12 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; 13 University of Ottawa, Ottawa, Ontario, Canada; 14 Swedish Medical Center, Seattle, WA
|
| |
|
|
|
|
|
